logo
Harvard argues in court that Trump administration's $2.6bn cuts are illegal

Harvard argues in court that Trump administration's $2.6bn cuts are illegal

The Guardian7 days ago
Harvard University appeared in federal court on Monday to make the case that the Trump administration illegally cut $2.6bn from the storied college – a major test of the administration's efforts to reshape higher education institutions by threatening their financial viability.
US district judge Allison Burroughs heard arguments from Harvard and the Department of Justice. The cuts, imposed earlier this year, have halted major research efforts and Harvard argues they are a politically motivated attempt to pressure the school into adopting federal policies on student conduct, admissions, antisemitism and diversity.
A ruling in favor of the university would revive Harvard's sprawling scientific and medical research operation and hundreds of projects that lost federal money.
'This case involves the government's efforts to use the withholding of federal funding as leverage to gain control of academic decisionmaking at Harvard,' the university said in its complaint. 'All told, the tradeoff put to Harvard and other universities is clear: allow the government to micromanage your academic institution or jeopardize the institution's ability to pursue medical breakthroughs, scientific discoveries, and innovative solutions.'
The case is being closely watched by other universities that have seen their research funds axed by the administration, which has suspended or threatened billions in grants and contracts from several institutions. The White House is reportedly close to finalizing a deal with Columbia University – the first institution it targeted for cuts – to restore $400m in funding in exchange for the university implementing a series of measures meeting the administration's ideological demands.
Harvard is the first – and so far only – university to sue.
The university has separately sued the administration over its revocation of Harvard's eligibility to host international students. (Trump has also threatened to revoke Harvard's tax-exempt status, but he has taken no action to that effect so far.)
Burroughs is overseeing both of Harvard's cases against the administration and in June issued an injunction stopping the government from barring foreign Harvard students from entering the country.
Monday's hearing was the first time the court heard arguments about the legality of the administration's funding cuts. The hearing ended without Burroughs issuing a ruling from the bench. A ruling is expected later in writing.
Harvard's lawsuit accuses Donald Trump's administration of waging a retaliation campaign against the university after it rejected a series of demands in an 11 April letter from a federal antisemitism taskforce.
The letter demanded sweeping changes related to campus protests, academics and admissions. For example, the letter told Harvard to audit the viewpoints of students and faculty and admit more students or hire new professors if the campus was found to lack diverse points of view. The letter was meant to address government accusations that the university had become a hotbed of liberalism and tolerated anti-Jewish harassment on campus.
A lawyer for the government, Michael Velchik, said in court on Monday that the government has authority to cancel research grants when an institution is out of compliance with the president's directives. He said episodes at Harvard violated Trump's order combating antisemitism.
Burroughs pushed back, questioning how the government could make 'ad-hoc' decisions to cancel grants and do so across Harvard without offering evidence that any of the research is antisemitic.
She also argued the government had provided 'no documentation, no procedure' to 'suss out' whether Harvard administrators 'have taken enough steps or haven't' to combat antisemitism.
'The consequences of that in terms of constitutional law are staggering,' Burroughs said during Monday's hearing. 'I don't think you can justify a contract action based on impermissible suppression of speech. Where do I have that wrong.'
Velchik said the case comes down to the government's choosing how best to spend billions of dollars in research funding.
'Harvard claims the government is anti-Harvard. I reject that,' Velchik said. 'The government is pro-Jewish students at Harvard. The government is pro-Jewish faculty at Harvard.'
Sign up to This Week in Trumpland
A deep dive into the policies, controversies and oddities surrounding the Trump administration
after newsletter promotion
Alan Garber, Harvard's president, pledged to fight antisemitism but said no government 'should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue'.
The same day Harvard rejected the demands, Trump officials moved to freeze $2.2bn in research grants. Linda McMahon, the US education secretary, declared in May that Harvard would no longer be eligible for new grants, and weeks later the administration began canceling contracts with Harvard.
As Harvard fought the funding freeze in court, individual agencies began sending letters announcing that the frozen research grants were being terminated. They cited a clause that allows grants to be scrapped if they no longer align with government policies.
Harvard, which has the nation's largest endowment at $53bn, has moved to self-fund some of its research, but warned it can't absorb the full cost of the federal cuts.
In court filings, the school said the government 'fails to explain how the termination of funding for research to treat cancer, support veterans, and improve national security addresses antisemitism'.
The Trump administration denies the cuts were made in retaliation, saying the grants were under review even before the April demand letter was sent. It argues the government has wide discretion to cancel contracts for policy reasons.
'It is the policy of the United States under the Trump administration not to fund institutions that fail to adequately address antisemitism in their programs,' it said in court documents.
Last month, the Trump administration formally issued a finding that the school tolerated antisemitism – a step that eventually could jeopardize all of Harvard's federal funding, including federal student loans or grants. The penalty is typically referred to as a 'death sentence'.
While Harvard's cases against the administration proceeds in court, the university is reportedly also negotiating with the administration for a deal that might end the dispute out of court.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Britain has no business laughing at Trump's EU trade deal
Britain has no business laughing at Trump's EU trade deal

The Independent

time22 minutes ago

  • The Independent

Britain has no business laughing at Trump's EU trade deal

In a world where Donald Trump's tariffs and trade wars make everyone a loser, are there any winners from his latest deal, sealed by a handshake with the president of the European Commission, Ursula von der Leyen, in a ballroom at one of the president's Scottish golf courses, of all places? One very clear loser is von der Leyen herself. If body language is anything to go by, she looked like she'd been badly bullied by the Big Orange Man – and, truthfully, so she had. In her own clipped remarks, she admits that a reduction in tariffs to 15 per cent, while 'not to be underestimated', was 'the best we could get'. President Macron has declared the US-EU trade deal a 'dark day' for Europe – and you can understand why. A general tariff level of 15 per cent – better than the 20 per cent proposed by Trump on his infamous 'Liberation Day' in April, and even better than the 30 per cent he was threatening a couple of weeks ago – is still prohibitive. It is certainly way above the 2 to 3 per cent levels that most EU exporters used to face. A trade war has been avoided, but this looks like the kind of deal the Americans have forced on the likes of Vietnam or Indonesia. So it is something of a humiliation for the mighty European Union, a global trade superpower. The feeling in some parts of Europe must be that if von der Leyen had played hard ball like the Chinese, a more evenly balanced and more advantageous relationship could have been reached in the long run. We will never know the truth about that. For European pride and for many of its great industrial concerns, the deal is disappointing, and will be expensive – the Volkswagen group is just one to speak out. But for European consumers, it is surely good news. They will be able to enjoy cheaper imports from the United States; it is American customers who will have to pay more for their French wines and Italian sports cars. Could it be that the EU's trade deal – which Trump has, well, trumpeted as the 'biggest ever', and whose biggest 'win' is the removal of a threat to raise tariffs to 30 per cent later this week – is marginally worse than the one Starmer did with Trump in May? Britain's trade deal lowered tariffs of UK goods imported into the US to 10 per cent, and imposed a lesser, 25 per cent tariff on the UK steel industry, with room for further concessions, while the 50 per cent 'worldwide rate' will remain for the EU. For those now cheering this as a rare Brexit benefit, it is a hollow victory. For the concessions to Britain are so minor, they cannot hope to make up for the ground lost since Brexit – essentially, a GDP loss in excess of 5 per cent. And we're not out of the rough, by any stretch. As Keir Starmer meets the US president for further trade discussions at the Trump Turnberry golf course, he will be acutely conscious of his counterpart's unpredictability. Starmer has milked the modest concessions he managed to wangle, particularly on cars and food standards, but much remains vague and far from nailed-down. The greatest danger is the fuzzy UK commitment to improve the trading environment for the US pharma groups will eventually mean an enormous increase in the drugs bill for the National Health Service, which it can ill-afford. Trump also omitted virtually the whole of the service sector from his UK deal, where the British actually enjoy a surplus, which is great until he decides otherwise. There are no legally binding rules here. The world economy remains highly inter-dependent, and globalisation, while receding, cannot sensibly be ended, as even Elon Musk tries to argue. All barriers to trade harm the country that erects them both directly and, in their depressing effects on world growth, indirectly. Consumers are charged more, on a highly regressive basis, companies are forced to pay more for inputs, and be less cost-effective, and competition and dynamic structural change are deliberately impeded. Whatever the details of the individual deals counties are trying to strike with one another, tariffs make us all poorer in the long run.

Is U.S. stock rally near 'Mag 7' turning point?
Is U.S. stock rally near 'Mag 7' turning point?

Reuters

time23 minutes ago

  • Reuters

Is U.S. stock rally near 'Mag 7' turning point?

ORLANDO, Florida, July 28 (Reuters) - As investors brace for the busiest week of the U.S. earnings season, with four of the 'Magnificent Seven' tech giants reporting, debate is picking up again about these megacap firms' influence over U.S. equity indexes and whether we could be seeing the beginnings of true market broadening. By some measures, this small clutch of tech titans' profits, market cap, and valuations as a share of the wider market has never been bigger. Broader indices are at record highs, but strip out these firms and the picture is much less rosy. Indeed, since the beginning of 2023, the S&P 500 composite - the benchmark 'market cap' index increasingly dominated by the 'Mag 7' - has gained 67%, more than double the 'equal-weight' index's 32%. Only two years ago, the S&P 500 composite/equal-weight ratio was 0.66, meaning the composite index was worth around two-thirds of the equal weight index. That ratio is now 0.84, the highest since 2003. There's good reason for that. According to Larry Adam, chief investment officer at Raymond James, 12-month forward earnings estimates for the S&P 500 have outpaced estimates for the equal-weight index by 14%. And Tajinder Dhillon, senior research analyst at LSEG, notes that the 'Mag 7' last year accounted for 52% of overall earnings growth. Many investors and analysts consider it unhealthy to have the fate of the entire market dependent on so few companies. It may be fine when they're flying high, but not so much if one or two of them take a dive. Plus, it makes stock picking more difficult. If the market basically goes where the 'Mag 7' or Nvidia go, why should an investor bother buying anything else? That's a recipe for market inefficiencies. There have recently been nascent signs that the market may be broadening out beyond tech and AI-related names, largely thanks to positive news on the trade front. Last week, the equal-weight index eclipsed November's high to set a fresh record. Raymond James's CIO Adam notes that the equal-weight index outperformed the S&P 500 last week for the fourth week in the last 13. More of the same this week would mark its first monthly outperformance since March. Can it hit this mark? Around 160 of the S&P 500-listed firms report this week, including Meta and Microsoft on Wednesday and Amazon and Apple on Wednesday. It's not a stretch to say these four reports will move the market more than the rest combined. LSEG's Dhillon says the Mag 7's share of total earnings growth is expected to fall to 37% this year and 27% next year. The expected earnings growth spread between Mag 7 and the wider index in the second quarter - 16.4% vs. 7.7% - is the smallest since 2023, and will shrink more in Q3, he adds. [Why does he believe this will be the case?] Larry Adam at Raymond James, however, thinks the recent market broadening is a "short-term normalization" rather than a "material shift". He thinks the earnings strength of the tech-related sectors justifies the valuation premium on these stocks. Regardless, what we know for sure is that fears about the market's concentration and narrowness have been swirling for years and there has yet to be a reckoning. The equal-weight index's rise to new highs last week suggests the rising tide is lifting all boats, not just the billionaire's yachts. Essentially, the Mag 7 and large caps are outperforming, but if you peel back the onion, other sectors like financials and industrials are also doing well. And look around the world. Many indices outside the U.S. that aren't tech-heavy are approaching or printing new highs also, like Britain's FTSE 100 and Germany's DAX. "To see the largest names leading isn't a worrisome sign, especially as they are backing it up with very strong earnings," says Ryan Detrick, chief market strategist at Carson Group. "This isn't a weak breadth market, it is broad based and a very healthy rally." This week's earnings might go some way to determining whether this continues for a while yet. (The opinions expressed here are those of the author, a columnist for Reuters)

Carlyle picks insiders for newly minted role of co-presidents after reshuffle
Carlyle picks insiders for newly minted role of co-presidents after reshuffle

Reuters

time23 minutes ago

  • Reuters

Carlyle picks insiders for newly minted role of co-presidents after reshuffle

July 28 (Reuters) - Alternative asset manager Carlyle (CG.O), opens new tab said on Monday it has rejigged its senior leadership ranks and named three of its veterans for its newly created role of co-presidents. Chief Financial Officer John Redett, credit head Mark Jenkins and client business head Jeff Nedelman will become the company's co-presidents, effective January 1, 2026. "These individuals, all Carlyle veterans, are proven leaders whose deep expertise and extensive experience will drive our next phase of growth," CEO Harvey Schwartz said in a statement. Since Schwartz took the helm in 2023, Carlyle has undergone a multi-year transformation to boost growth by rejigging leadership and realigning its compensation model, while expanding beyond its private equity roots. The company said the leadership appointments would bolster its ability to operate at scale in a competitive environment. In the newly created roles, the trio will closely work with Schwartz to further Carlyle's growth ambitions, the firm said. In addition to their new roles, Jenkins will lead the credit and insurance business, while Nedelman will continue to head the client business. Redett will lead Carlyle's private equity business as well as oversee the corporate private equity and real assets businesses. Justin Plouffe, who is the current deputy chief investment officer for Carlyle's credit business, will succeed Redett as the finance boss of Carlyle next year, the company said. Michael Wand, who oversees the firm's private equity business in Europe, will become the head of EMEA investments and work in tandem with the company's co-presidents. Admiral James Stavridis, the former Supreme Allied Commander at NATO and Carlyle's vice chair of global affairs, will become the company's vice chairman. With $453 billion of assets under management, Carlyle deploys private capital across private equity, credit and its AlpInvest business. Carlyle is set to report its quarterly results next week. Its stock has jumped nearly 26% this year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store